What is HC Wainwright’s Estimate for TRDA FY2025 Earnings?

Entrada Therapeutics, Inc. (NASDAQ:TRDA) – Analysts at HC Wainwright upped their FY2025 EPS estimates for shares of Entrada Therapeutics in a report released on Tuesday, November 11th. HC Wainwright analyst R. Selvaraju now expects that the company will earn ($3.67) per share for the year, up from their previous estimate of ($3.78). The consensus estimate for Entrada Therapeutics’ current full-year earnings is $1.12 per share. HC Wainwright also issued estimates for Entrada Therapeutics’ Q4 2025 earnings at ($1.14) EPS, Q2 2026 earnings at ($1.24) EPS, Q3 2026 earnings at ($0.98) EPS, Q4 2026 earnings at ($0.81) EPS and FY2026 earnings at ($4.21) EPS.

Several other research firms have also weighed in on TRDA. Roth Capital set a $13.00 price target on Entrada Therapeutics in a report on Thursday, November 6th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Entrada Therapeutics in a research note on Wednesday, October 8th. Zacks Research raised shares of Entrada Therapeutics to a “hold” rating in a research note on Friday, August 8th. Finally, Wall Street Zen lowered shares of Entrada Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, August 9th. One investment analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $20.67.

Entrada Therapeutics Price Performance

NASDAQ:TRDA opened at $8.01 on Thursday. The firm has a market capitalization of $306.14 million, a price-to-earnings ratio of -3.22 and a beta of -0.08. The business has a 50 day simple moving average of $6.10 and a 200-day simple moving average of $6.68. Entrada Therapeutics has a 1 year low of $4.93 and a 1 year high of $21.79.

Entrada Therapeutics (NASDAQ:TRDA) last released its quarterly earnings results on Thursday, November 6th. The company reported ($1.06) EPS for the quarter, missing the consensus estimate of ($1.04) by ($0.02). Entrada Therapeutics had a negative return on equity of 26.42% and a negative net margin of 168.16%.The company had revenue of $1.61 million during the quarter, compared to analysts’ expectations of $8.62 million.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. State of Wyoming increased its position in shares of Entrada Therapeutics by 130.9% during the second quarter. State of Wyoming now owns 7,575 shares of the company’s stock worth $51,000 after acquiring an additional 4,295 shares during the period. AXQ Capital LP bought a new stake in shares of Entrada Therapeutics in the 3rd quarter valued at about $67,000. Occudo Quantitative Strategies LP bought a new position in shares of Entrada Therapeutics during the second quarter valued at approximately $68,000. Inscription Capital LLC bought a new position in Entrada Therapeutics in the third quarter worth approximately $69,000. Finally, IHT Wealth Management LLC bought a new stake in Entrada Therapeutics during the 2nd quarter valued at $72,000. 86.39% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other Entrada Therapeutics news, major shareholder Bros. Advisors Lp Baker bought 100,736 shares of the firm’s stock in a transaction dated Wednesday, November 12th. The stock was acquired at an average cost of $7.76 per share, for a total transaction of $781,711.36. Following the completion of the transaction, the insider owned 4,664,924 shares in the company, valued at $36,199,810.24. This trade represents a 2.21% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders acquired a total of 178,044 shares of company stock valued at $1,352,568 in the last 90 days. Company insiders own 8.11% of the company’s stock.

Entrada Therapeutics Company Profile

Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.